DIVA Expertise’s Post

The October issue of Cell Press Trends in Pharmacological Sciences is now available online! Explore the latest insights on various topics including targeting white adipose tissue for combating insulin resistance, SYK targeting in solid tumors, and quantum computing applications in clinical trial design(Hakan Doga, PhD, Aritra Bose, Daniel Blankenberg). Don't miss the Drug of the Month highlighting Ensifentrine for chronic obstructive pulmonary disease (Sandra HUBERT,Ayrin KÖK-CARRIERE, &Frédéric De Ceuninck). Reach out to me on here or at the Trends in Pharmacological Sciences website if you have an idea for a Drug of the Month, Scientific Life, Opinion, or Review article you wish to publish. #Pharmacology #Research #DrugDiscovery #ScienceCommunity

🧬𝗛𝘂𝗺𝗮 𝗣𝗮𝗻𝗰𝗿𝗲𝗼𝗠𝗮𝘁𝗿𝗶𝘅: 𝗘𝗹𝗲𝘃𝗮𝘁𝗶𝗻𝗴 𝗣𝗮𝗻𝗰𝗿𝗲𝗮𝘁𝗶𝗰 𝗥𝗲𝘀𝗲𝗮𝗿𝗰𝗵 Huma PancreoMatrix is a groundbreaking pancreatic ECM derived from nutrient-rich human pancreatic tissue. It retains essential native matrix proteins and growth factors, providing an optimal environment for advanced cell culture applications. Ideal for in-vitro pancreatic models, disease studies, and #tissueengineering, Huma PancreoMatrix facilitates accurate disease modeling and supports therapeutic development. Be part of the next frontier in pancreatic research and #regenerativemedicine with our clinically relevant, cost-effective, and reliable #biomaterials. #BiomedicalResearch #biotech #Biomedical Learn more about how Huma PancreoMatrix can help your research: https://lnkd.in/gK2h5Rx9 

Ultrasound Guided Synovial Biopsies can be easily performed by an ultrasound-trained rheumatologist and can help advance research to learn more about various arthritides and how they can be optimally treated. Check out the the latest Best Practices in Rheumatology article on UGSBy by our USSONAR UGSBy faculty https://lnkd.in/dnRUrW7U Diane Horowitz Arthur Mandelin, MD, PhD, FACR, RhMSUS, RMSK #AmiBenArtziMDRhMSUS #DarrenTabechianMD #precisionmedicine #spatialtranscriptomics #rheumatoidarthritis #ultrasound #POCUS #rheumatology

AZAFAROS B.V. is thrilled to make two important announcements:  📜8 posters selected for presentation at upcoming international conference on lysosomal storage disorders, the WORLDSymposium™. 📊 Results of the first-in-human Phase 1 study testing the safety in healthy volunteers of our lead asset, nizubaglustat, have been published in leading peer-reviewed journal, Molecular Genetics and Metabolism.   Four posters showing baseline data from our landmark natural history (PRONTO) study in patients with GM1 and GM2 gangliosidoses were among the eight selected for presentation at the WORLDSymposium™, to be held at the Manchester Grand Hyatt Hotel in San Diego from 📅 February 4-9.    Other posters include the design of our Phase 2 RAINBOW study investigating nizubaglustat in patients with GM2 gangliosidosis and Niemann-Pick disease type C (NPC). Additionally, we will present results from a novel human 🧠 brain organoid model of GM1 gangliosidosis in collaboration with the Australian Institute for Bioengineering and Nanotechnology AIBN. Azafaros is proud to present these clinical trial achievements 🎯 as we work closely with investigators, patient advocacy groups and investors towards finding treatment solutions for families and patients with GM1, GM2 and NPC.     📰 You can read the full story here: https://lnkd.in/e8k8pmc5   #Biotech, #clinicaltrials, #investors, #GM1, #GM2, #NPC, #organoid, #worldsymposium, #Teamwork, #RareDiseases, #Azafaros

🧬 𝗕𝗼𝗻𝗲-𝘁𝗮𝗿𝗴𝗲𝘁𝗶𝗻𝗴 #𝗟𝗡𝗣 𝗳𝗼𝗿 #𝗺𝗥𝗡𝗔 𝗱𝗲𝗹𝗶𝘃𝗲𝗿𝘆 𝘁𝗼 𝘁𝗵𝗲 𝗯𝗼𝗻𝗲 𝗺𝗶𝗰𝗿𝗼𝗲𝗻𝘃𝗶𝗿𝗼𝗻𝗺𝗲𝗻𝘁? ◽𝗬𝗼𝗼𝗻 𝗲𝘁 𝗮𝗹. 𝗶𝗻 𝗔𝗻𝗴𝗲𝘄𝗮𝗻𝗱𝘁𝗲 𝗖𝗵𝗲𝗺𝗶𝗲 (Open Access, 𝗟𝗶𝗻𝗸 𝗶𝗻 𝗰𝗼𝗺𝗺𝗲𝗻𝘁𝘀) led by Michael J Mitchell from University of Pennsylvania developed bisphosponate-linked ionizable lipids/LNPs which may provide targeted nucleotide therapy for the bone microenvironment. ◽𝗖𝗼𝗻𝘁𝗲𝗻𝘁 Bone tissue consists of osteoblasts. Disruption in the signaling pathways of these cells can result in diseases such as osteoporosis and osteosarcoma. However, delivery to the bone microenvironment remains a significant challenge. Yoon et al. introduce bone-targeting ionizable lipids (PIP-BP) with a piperazine backbone, which interacts strongly with hydroxyapatite, a key component of mineralized tissues. A top performaning lipid 'Type3-P1-C12' showed high luciferase expression in vitro and in vivo with biocompatibility and low toxicity. ◽ 𝗧𝗮𝗸𝗲𝗮𝘄𝗮𝘆 Bone-targeting LNP (PIP-BP LNPs) were rationally designed to target the bone microenvironment. In addition, immobilized PIP-BP LNPs on a hydroxyapatite surface can be analysed using AFM, QCM-D and cryo-TEM. ◽ 𝗚𝗲𝗻𝗲 𝗗𝗲𝗹𝗶𝘃𝗲𝗿𝘆 ｜ 𝗖𝗲𝗹𝗹 & 𝗚𝗲𝗻𝗲 𝗧𝗵𝗲𝗿𝗮𝗽𝘆 𝗡𝗲𝘄𝘀 Follow me for more breaking research & news.

🔬Citation Break!📖 This citation investigates the relationship between Beta-Amyloid peptides and extracellular vesicles (EVs). The researchers wish to show how forms of Aβ might travel throughout the body, and how this process might be involved in the pathology of Alzheimer's Disease. Several rPeptide products were used for the authors’ experiments, SIMOA assays, and other analyses during their research: Beta-Amyloid (1-40) and (1-42) NaOH (A-1155 and A-1165) and sequence scrambled versions of each (A-1003 and A-1004). Paper: https://t.ly/b0LFC Beta-Amyloid Products: https://t.ly/w-f7N #Research #Development #rPeptide #Alzheimers #Experiment #NaOH #Scrambled #BetaAmyloid

📢Daily Paper Sharing: Advances in rationally engineered cytokines for precision therapy in diabetic wound healing hashtag #diabetic #wound 👥 Authors: Xinxin Zhang, Tingting Wang, Xiangqing Fan, Tianze Zhang, Rui Qiu, Yuqi Wu, Meixia Wang, Yizhi Zhang, Meng Li, Na Cai , Ying Guan, Hong-Hui Wang 🔑 Keywords: Cytokine engineering, diabetic wound healing, precision therapy, synthetic biology, rationally designed cytokines, molecular modifications 🎯 "...This review not only provides valuable perspectives on the future research directions but also offers insights into the potential clinical applications of these innovative therapies, aiming to significantly improve the outcomes for patients suffering from diabetic wounds." 👤 Academic Editor: Dominique J. Charron, Hospital Saint Louis, France 🔗 Read the full article: https://lnkd.in/gpBpk8VY

🔬 Cutting-edge Research Share! 🔥 Diabetic wound healing takes a leap with rational cytokine engineering! 🩹 Driven by Xinxin Zhang et al., explore precision therapies that merge #syntheticbiology & molecular wizardry. A must-read for healthcare innovators! 🌟 #DiabeticWound #PrecisionMedicine

📢Daily Paper Sharing: Advances in rationally engineered cytokines for precision therapy in diabetic wound healing hashtag #diabetic #wound 👥 Authors: Xinxin Zhang, Tingting Wang, Xiangqing Fan, Tianze Zhang, Rui Qiu, Yuqi Wu, Meixia Wang, Yizhi Zhang, Meng Li, Na Cai , Ying Guan, Hong-Hui Wang 🔑 Keywords: Cytokine engineering, diabetic wound healing, precision therapy, synthetic biology, rationally designed cytokines, molecular modifications 🎯 "...This review not only provides valuable perspectives on the future research directions but also offers insights into the potential clinical applications of these innovative therapies, aiming to significantly improve the outcomes for patients suffering from diabetic wounds." 👤 Academic Editor: Dominique J. Charron, Hospital Saint Louis, France 🔗 Read the full article: https://lnkd.in/geqfCwRZ

Our CEO, Shehnaaz Suliman, M.D. (MB ChB), M.B.A., M.Phil., discussed on Locust Walk how we prioritized research for our Selective Organ Targeting (SORT) Lipid Nanoparticle (LNP) platform: “We followed the science. We started in the lungs because no one else had gone there. And also because it’s about as far away […] from the liver as you can go. Showing proof of concept there with a novel formulation that is clearly not the liver de-risks not just the program and the modality, but the overall platform as well.” Utilizing our SORT LNP platform, we are working on therapies to reach all patients, including those for whom existing options are insufficient. Learn more about the next generation of genetic medicine delivery via the link below: https://lnkd.in/gjWyq3MZ